Laboratorios Farmaceuticos Rovi (0ILL) AI Stock Analysis

Compare

0 Followers

Top Page

Laboratorios Farmaceuticos Rovi (0ILL) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap

€2.80B

Dividend Yield1.62%

Average Volume (3M)25.95K

Price to Earnings (P/E)20.3

Beta (1Y)0.73

Revenue GrowthN/A

EPS GrowthN/A

CountryUK

Employees2,197

SectorHealthcare

Sector Strength42

IndustryBiotechnology

Share Statistics

EPS (TTM)0.35

Shares Outstanding51,235,764

10 Day Avg. Volume13,401

30 Day Avg. Volume25,947

Financial Highlights & Ratios

PEG Ratio0.50

Price to Book (P/B)4.71

Price to Sales (P/S)0.00

P/FCF Ratio35.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€90.00

Price Target Upside63.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Laboratorios Farmaceuticos Rovi Business Overview & Revenue Model

Company DescriptionLaboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

How the Company Makes Money

Laboratorios Farmaceuticos Rovi Earnings Call Summary

Earnings Call Date:May 08, 2025

(Q4-2024)

% Change Since: 7.81%|

Next Earnings Date:Jul 23, 2025

Earnings Call Sentiment Neutral

The earnings call reflects a challenging year for Rovi with significant declines in operating revenue, CDMO sales, EBITDA, and net profit, primarily due to decreased COVID-19 vaccine manufacturing revenues. However, there are positive aspects such as growth in the specialty pharma business, particularly with Okedi and Bemiparin, and improvements in ESG ratings. The company is investing in future growth, particularly in the CDMO segment, but faces short-term operational and financial challenges.

Q4-2024 Updates

Positive Updates

Specialty Pharma Business Growth

Sales of the specialty pharmaceutical business increased by 2% in 2024, reaching €427.5 million, driven by products like Okedi, Neparvis, and contrast imaging agents.

Okedi Risperidone ISM Performance

Sales of Okedi doubled in 2024, reaching €28.8 million, and it was launched in new markets including Finland, the rest of the Nordic countries, Australia, Taiwan, and the Netherlands.

Bemiparin Sales Increase

Bemiparin international sales grew by 16% with strong contributions from China, Turkey, and Greece, despite an overall slow down in the Heparin franchise.

ESG Improvements

Rovi improved its ESG risk rating to 16.1 from 16.4 in the previous year and was ranked fifth in the world ESG risk ranking among 424 pharmaceutical companies.

Future CDMO Growth Prospects

A new agreement for pre-filled syringes with a global pharmaceutical company is expected to increase CDMO revenue by 20% to 45% over 2023 sales starting in 2027.

Negative Updates

Operating Revenue Decline

Total operating revenues fell by 7.9% to €763.7 million due to decreased revenues from COVID-19 vaccine manufacturing.

CDMO Sales Decline

CDMO sales decreased to €336.2 million due to lower revenues from the COVID-19 vaccine manufacturing compared to 2023.

Heparin Franchise Sales Decline

Sales of the Heparin franchise decreased by 2% in 2024, with Enoxaparin biosimilar sales dropping by 6%.

EBITDA and Net Profit Decrease

EBITDA decreased by 15% to €207.4 million, and net profit dropped by 20% to €136.9 million in 2024 compared to 2023.

Increased SG&A Expenses

Selling, general, and administrative expenses increased by 12% due to higher employee benefit expenses and non-recurrent expenses.

Company Guidance

In the call, Rovi provided guidance for 2025, expecting operating revenue to decrease by a mid-single-digit percentage compared to 2024. The company highlighted a 7.9% decline in operating revenue to €763.7 million in 2024, primarily due to reduced CDMO sales of €336.2 million, which were impacted by lower revenues from COVID-19 vaccine manufacturing. Despite this, the specialty pharmaceutical business saw a 2% increase in sales to €427.5 million, driven by products like Okedi, which doubled its sales to €28.8 million. Rovi's gross margin improved by 370 basis points to 62.7%, although EBITDA decreased by 15% to €207.4 million, and net profit dropped 20% to €136.9 million. The company also reported a significant reduction in raw material prices for low-molecular-weight heparins, which fell by 54%. Rovi's CapEx in 2024 was €62.2 million, with investments in expanding CDMO capacities and other strategic projects. The company remains optimistic about future growth driven by its specialty pharma area, CDMO business, and ongoing investments in R&D and infrastructure.

Laboratorios Farmaceuticos Rovi Financial Statement Overview

Summary

Laboratorios Farmaceuticos Rovi shows a solid financial foundation with strong profitability and a stable balance sheet. While recent revenue growth has been challenging, the company maintains operational efficiency and financial stability. Continued focus on cash flow management will be key to sustaining growth and supporting strategic initiatives.

Income Statement

Positive

Laboratorios Farmaceuticos Rovi exhibits strong profitability metrics with a consistent high gross profit margin and net profit margin over the years. However, recent revenue growth has slowed, with a slight decline in the most recent year. EBIT and EBITDA margins remain robust, indicating operational efficiency despite the revenue dip.

Balance Sheet

Very Positive

The company maintains a healthy balance sheet with a favorable debt-to-equity ratio, indicating prudent leverage levels. The return on equity remains strong, reflecting efficient use of shareholder funds. Equity ratio shows stability, underscoring financial resilience in the industry.

Cash Flow

Positive

Operating cash flow is strong, supporting net income effectively, though free cash flow growth has been inconsistent. The company has demonstrated capability in generating free cash flow but should focus on sustaining and improving cash flow generation to support future growth.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
763.75M	829.51M	817.70M	648.68M	419.96M
	Gross Profit
478.35M	483.34M	519.61M	384.82M	241.31M
	EBIT
179.54M	220.25M	255.85M	181.57M	74.68M
	EBITDA
207.69M	245.81M	281.49M	204.72M	93.28M
	Net Income Common Stockholders
136.88M	170.34M	199.67M	153.08M	61.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
27.41M	25.32M	124.94M	99.03M	53.16M
	Total Assets
832.02M	799.88M	878.70M	732.68M	574.44M
	Total Debt
114.41M	65.43M	72.14M	73.14M	73.52M
	Net Debt
87.22M	40.10M	-52.81M	-25.89M	20.36M
	Total Liabilities
250.48M	256.39M	357.32M	261.70M	200.74M
	Stockholders Equity
572.03M	539.39M	520.01M	470.98M	373.70M
Cash Flow		Free Cash Flow
76.06M	58.06M	186.21M	108.50M	7.18M
	Operating Cash Flow
138.28M	113.25M	237.60M	149.44M	46.88M
	Investing Cash Flow
-81.06M	-52.03M	-57.15M	-40.84M	-39.63M
	Financing Cash Flow
-55.36M	-160.84M	-154.54M	-62.73M	-21.52M

Laboratorios Farmaceuticos Rovi Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0ILL		€2.80B	20.25	25.24%	1.62%	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
0O9B		€2.37B	232.50	0.69%	1.33%	―	―
0K9H		€1.34B	11.98	16.04%	2.97%	―	―
0RDV		€6.32B	26.84	3.37%	―	―	―
0RB1		€263.54M	23.59	5.11%	1.24%	―	―
PHMMF		$1.72B	78.75	10.15%	0.73%	―	―

* Healthcare Sector Average

Performance Comparison

GB:0ILL

Laboratorios Farmaceuticos Rovi

55.20

-32.91

-37.35%

GB:0O9B

Almirall

11.16

1.70

17.97%

GB:0K9H

Faes Farma

4.26

0.60

16.39%

GB:0RDV

Grifols

7.70

1.14

17.38%

GB:0RB1

LABORATORIO REIG JOFRE

3.19

0.13

4.25%

PHMMF

Pharma Mar SA

97.58

57.03

140.64%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.